logo
  Join        Login             Stock Quote

Pfizer Moving Antibacterial R&D From US To Shanghai

 March 16, 2011 02:49 PM
 


Pfizer (NYSE: PFE) will close its R&D facility in Groton, Connecticut and move its antibacterials research operations to Shanghai. Although all major multinationals are doing research in China, it is highly unusual for a big pharma to move an entire lab there.

The switch will be gradual, according to Pfizer. Some researchers will remain at their present facility for up to two years, seeing their projects through to completion and also allowing Pfizer time to complete construction on its Shanghai lab. Pfizer's antibacterial operation is developing antibiotics to counteract superbugs such as MRSA that are resistant to commonly available treatments.

Besides the cost advantage of doing drug research in China and the talent available there, ex-Pfizer executives commented that a Shanghai facility helps gain favor with the SFDA, which comes in handy when a company like Pfizer seeks China approval for its drugs.

Pfizer had previously announced it would close the Groton lab. In 2009, the company indicated it would close six of its twenty R&D global facilities as it rationalized its operations and cut costs. At the same time, the company was bulking up its Shanghai R&D operation. Pfizer opened its Shanghai R&D Center in 2005 and has been steadily been adding staff since then.
iOnTheMarket Premium
Advertisement

Advertisement


Comments Closed


rss feed

Latest Stories

article imageFour Stocks in the Dow Making Fresh 52 Week Lows

“What gets weak tends to get weaker; what gets strong tends to get read on...

article imageGreece And The Cemetery For Your Wealth

The Greek default is merely the opening act of the worst sovereign-debt crisis in history. By the time it read on...

article imageAll Signs Point To Higher Gold Prices

In the face of historic monetary stimulus from nearly every major central bank in the world over the past read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.